Expanded clinical trials of treatments for multiple sclerosis: copolymer 1 (COP-1) treatment investigational new drug (IND) program.
Stark
Y
Y
D002985:Clinical Protocols / Q000592:standards; D002986:Clinical Trials as Topic / Q000379:methods / Q000592:standards*; D004311:Double-Blind Method; D017277:Drug Approval; D004345:Drug Industry; D015507:Drugs, Investigational / Q000627:therapeutic use*; D017408:Guidelines as Topic; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000627:therapeutic use*; D006377:T-Lymphocytes, Helper-Inducer / Q000276:immunology; D014481:United States; D014486:United States Food and Drug Administration
D015507:Drugs, Investigational; D010455:Peptides; C021759:(T,G)-A-L